• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

The use of metronomic chemotherapy in dogs

November 1, 2007
Mona Rosenberg, DVM, DACVIM (Oncology)

While this was a relatively small study (nine dogs were treated with LDC), this paper suggests that LDC may be an effective alternative to MTD chemotherapy in dogs with hemangiosarcoma.

Over the last several years, human and veterinary researchers have been interested in therapies that target angiogenesis. If we can prevent blood-vessel proliferation by the tumor, we may be able to prevent progression of many cancers.

This type of therapy, often referred to as low-dose continuous chemotherapy (LDC), may have significant advantages over standard, high-dose therapy, in that fewer severe side effects may be seen, in addition to improved anti-tumor effects.

Also, we may be able to administer drugs over a longer period, because there is minimal need to allow the body to recover. Eliminating the need for breaks between cycles of maximally tolerated dosage (MTD) chemotherapy may lead to improved tumor-cell kill, as the endothelial lining does not have a chance to regenerate with the LDC approach.

Chemotherapy drugs work, not by specifically targeting tumor cells, but by interfering with cell division via inhibition of microtubule formation, DNA replication, etc. Thus, these drugs also will damage the normally rapidly dividing population of cells as well, such as the bone-marrow progenitor cells, intestinal mucosal-lining cells and vascular endothelial cells. This often results in a narrowed therapeutic index when conventional MTD is used.

Advertisement

Furthermore, based on the fact that quality of life is an absolute requirement in our animal patients, as veterinary oncologists our MTD is less than that in human patients. Therefore, we struggle to cure most of our patients because it is inappropriate for us to be as aggressive in our therapies.

High-dose chemotherapy, with the required breaks in treatment, not only allows for resolution of the drug-induced bone-marrow suppression, but seems to provide time for the endothelial cells to regenerate.

Using LDC provides continuous suppression of the repair process of the blood vessel, thus robbing tumor cells of their nutritional support. Interestingly, even if a tumor cell is resistant to a particular chemotherapy agent at the MTD, the vascular endothelial cells still are sensitive when LDC is employed.

In a paper by Lana, et al. (J Vet Intern Med 2007; 21:764-769), dogs with Stage II hemangiosarcoma were treated with LDC and survival times were compared to dogs treated with conventional MTD chemotherapy. The LDC was well tolerated over a period of six months. The median overall survival time and median disease-free interval were 178 days. For dogs treated with doxorubicin chemotherapy, the overall survival time and disease-free interval were 133 and 126 days, respectively.

While this was a relatively small study (nine dogs were treated with LDC), this paper suggests that LDC may be an effective alternative to MTD chemotherapy in dogs with hemangiosarcoma.

Perhaps future studies will determine the true role of this new approach to therapy for animals with malignant cancers.

Mona Rosenberg

Dr. Rosenberg, a diplomate of the ACVIM in oncology, received her veterinary degree from UC-Davis in 1987. She completed her internship and residency in medical oncology at the Animal Medical Center. Dr. Rosenberg was awarded the David S. Brody Award for Clinical Excellence in 1990 for her work in lymphoma and hypercalcemia. In 1992, she founded the Veterinary Cancer Group. Having built two comprehensive cancer centers in Southern California, Dr. Rosenberg leads the largest private animal-oncology practice in the nation.

Related Content:

Oncology
Superficial radiation therapy may serve as promising cutaneous MCT treatment
Superficial radiation therapy may serve as promising cutaneous MCT treatment
VolitionRx publishes new research in PLOS ONE
VolitionRx publishes new research in PLOS ONE
Battling the equine sarcoid
Battling the equine sarcoid

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement